Effective real‐world outcomes of remdesivir provided under compassionate access for moderate/severe <scp>COVID</scp>‐19 in Australia
Clinical recovery and mortality with remdesivir in a real-world setting were at least comparable to randomised clinical trial data, confirming effectiveness in this setting. Use of adjunctive glucocorticoids in this cohort likely contributed to the improved outcomes.
Authors
- Kumar Visvanathan (ORCID: https://orcid.org/0000-0002-1176-5442)
- Tony M. Korman (ORCID: https://orcid.org/0000-0002-6155-8353)
- Craig Aboltins (ORCID: https://orcid.org/0000-0002-7578-882X)
- Peter Kelley (ORCID: https://orcid.org/0000-0002-2291-9363)
- Jonathan Darby (ORCID: https://orcid.org/0000-0001-5462-5215)
- Robert G Stolz (ORCID: https://orcid.org/0000-0003-0032-5254)
- Leong Shuen Loo
- Paul Wynn
- Nicole Gilroy
- Stephen Guy (ORCID: https://orcid.org/0000-0003-1820-3802)
- Joe Sasadeusz (ORCID: https://orcid.org/0000-0001-7438-0382)
- Marion Kainer (ORCID: https://orcid.org/0000-0001-7678-8744)
- Alice Liu (ORCID: https://orcid.org/0000-0001-6816-3234)
- Patrick G. P. Charles
Institutions
- Northern Health (AU)
- Peter MacCallum Cancer Centre (AU)
- Monash Medical Centre (AU)
- Westmead Hospital (AU)
- St Vincent's Hospital Melbourne (AU)
- Eastern Health (AU)
- Western Health (AU)
- Peninsula Health (AU)
- Melbourne Health (AU)
- Austin Health (AU)
Publication Details
- Journal
- Internal Medicine Journal
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1111/imj.70173
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences